We will begin momentarily at 2pm ET

Recordings will be available to ACS members after three weeks

www.acs.org/acswebinars

Contact ACS Webinars ® at acswebinars@acs.org

Have Questions?

“Why am I muted?”
Don’t worry. Everyone is muted except the presenter and host. Thank you and enjoy the show.

Type them into questions box!

Contact ACS Webinars ® at acswebinars@acs.org
Have you discovered the missing element?

www.acs.org/2joinACS

Find the many benefits of ACS membership!

---

Benefits of ACS Membership

Chemical & Engineering News (C&EN)
The preeminent weekly news source.

NEW! Free Access to ACS Presentations on Demand®
ACS Member only access to over 1,000 presentation recordings from recent ACS meetings and select events.

NEW! ACS Career Navigator
Your source for leadership development, professional education, career services, and much more.

www.acs.org/2joinACS
Like us on Facebook!

ACS Short Courses

Monday - Thursday,
October 6-9, 2014
Boston, MA

Courses scheduled to be held include:

- Critical cGMP and ICH regulations for Pharmaceutical Laboratories
- Drug-like Properties: Optimizing Pharmacokinetics and Safety in Drug Discovery
- Analytical Method Transfer of Pharmaceutical Products

Register at http://proed.acs.org/Boston
How has ACS Webinars® benefited you?

“In my opinion, The Role of Chemistry in Clinical Trials was the best webinar presented in the series. There was a balance between theory and practice. The key studies were very interesting. The speakers were relaxed and confident in their knowledge, I felt like I was participating in a meeting of masters.”

Fan of the Week
Dr. Alicja Kluczyk
Faculty of Chemistry
University of Wroclaw
Wroclaw, Poland

Be a featured fan on an upcoming webinar! Write to us @ acswebinars@acs.org

facebook.com/acswebinars
@acswebinars
youtube.com/acswebinars

Stay connected...
Email us!
acswebinars@acs.org
Hungry for a brain snack?

“ACS Webinets™ are 2 minute segments that bring you valuable insight from some of our most popular full length ACS Webinars®.”

See all the ACS Webinets at youtube.com/acswebinars

Beginning in 2014 all recordings of ACS Webinars will be available to current ACS members three weeks after the Live broadcast date.

Live weekly ACS Webinars will continue to be available to the general public.

Contact ACS Webinars® at acswebinars@acs.org
Upcoming ACS Webinars®
www.acs.org/acswebinars

Thursday, October 2, 2014
“The Chemistry of Death”
Lucas Zarwell, Chief Toxicologist, DC Medical Examiner’s Office
Dr. Darren Griffin, Professor of Genetics, University of Kent

Thursday, October 9, 2014
“From Molecules to Medicine: How Structure Helps Cure Disease”
Dr. Greg Petsko, Weill Cornell Medical College
Dr. Martha Teeter, American Crystallographic Association

Did you miss the past recordings in the Drug Discovery Series?

Next in the Drug Discovery Series!

“Future of Drug Discovery: Challenges, Risks, and Rewards”

Thursday, October 30, 2014

“Pharmacoeconomics and IP Strategies in Drug Development”

Dr. Robert Koch
Partner and IP Specialist, Milbank

Dr. Joseph Fortunak
Professor of Chemistry, Howard University

Dr. Richard Wilike
VP of Outcomes & Evidence, Pfizer

Recordings will be available to ACS members after three weeks

www.acs.org/acswebinars

Contact ACS Webinars ® at acswebinars@acs.org
What Will You Learn?

- What “cost-effectiveness” means for drug products and how payers perceive their value
- How patient outcomes fit into pharmacoeconomics
- The role that pharmacoeconomics plays in the drug development cycle
What Will You Learn?

- What “cost-effectiveness” means for drug products and how payers perceive their value

- How patient outcomes fit into pharmaco economics

- The role that pharmaco economics plays in the drug development cycle

The Healthcare Environment Has Changed

20th century:
- Clinical Development
- Marketing authorization
- Marketing & Sales

21st century:
- Clinical Development
- Marketing authorization
- Marketing & Sales

Market Access
Market Access: Affected by Many Factors

Medical

- Regulatory approval
- Comparative effectiveness/relative effectiveness
- External health system environment
- Health technology assessment
- Pharmacoeconomic evaluation
- Conditional reimbursement
- Pricing & cost containment

Economic

Where is Pharmacoeconomic Evaluation Relevant?

There are 4 Archetypes of Payers

Negotiations-driven markets
(France, Italy, Spain): National pricing and reimbursement agencies with specific requirements, often lengthy negotiations process.

HTA-driven markets (UK, Neth., Canada, Australia): Quantitative, formalistic approach driven by health economics.

Free pricing markets (USA): Independent insurance companies and payer entities, laws of market economics are most relevant here. Pharmacoeconomic evaluation used by some payers.

Non-reimbursed markets
(emerging markets): Still need to price products and get government approval.
Pharmacoeconomics and the Basic Elements of Measuring Value

Cost: How does the new product affect overall treatment costs?

Benefit: What's the net health benefit from the new product, compared to others?

Cost-benefit (aka cost-effectiveness) ratio:
What's the cost per additional unit of health? Is the patient or society willing to pay that much for the new product?

Pharmacoeconomic Evaluation Parameters

Target population

New product

Current practice

Patient benefits
- effectiveness
- survival
- quality of life
- patient preferences

Direct costs (impact on health resource use)
- hospital care
- outpatient care
- primary care
- medication
- long-term care

Indirect costs
- lost productivity
- time lost from usual activities
- social costs (e.g., caregiver time, childcare)
How is Cost-effectiveness Judged?

- **Cost-Minimization**
  - Reducing overall treatment costs is always good, as long as outcomes are no worse
  - Most common situation is when drugs go generic, so choosing generic drugs over branded drugs in the same class usually reduces treatment costs

- **Cost-effectiveness**
  - Within disease
    - Reasonable cost per "endpoint improvement", e.g., cost per stroke avoided, compared to other therapies
    - Varies by disease
  - Across diseases
    - Pharmacoeconomic endpoint is "quality-adjusted life-year" (QALY); can be used in any disease
    - Choose therapies with a reasonable cost per quality-adjusted life year saved
    - In the UK, "reasonable" means less than £20,000 - £30,000 per QALY
    - In the US, "reasonable" is more like $100,000 per QALY, though it's not specifically set by most payers and can vary by condition

Audience Survey Question

Which of the following countries was the first European country to establish pharmacoeconomic guidelines?

- Belgium
- The Netherlands
- Portugal
- Germany
- France
## Pharmacoeconomic Guidelines Around the World

### COUNTRY-SPECIFIC PHARMACOECONOMIC GUIDELINES

<table>
<thead>
<tr>
<th>Country/Region</th>
<th>Published PE Recommendations</th>
<th>PE Guidelines</th>
<th>Submission Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Africa</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Africa</td>
<td>2010</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cuba</td>
<td>2003</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>2008</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>America-Centre and South</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>United States</td>
<td>2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>2006</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>America-North</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>United States</td>
<td>2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taiwan</td>
<td>2006</td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Korea</td>
<td>2006</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Israel</td>
<td>2010</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thailand</td>
<td>2008</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Asia</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>China Mainland</td>
<td>2013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baltic (Latvia, Lithuania, Estonia)</td>
<td>2002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>2003</td>
<td></td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>2004</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ireland</td>
<td>2010</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Netherlands</td>
<td>2006</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norway</td>
<td>2007</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portugal</td>
<td>1998</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovak Republic</td>
<td>2008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>2003</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Europe</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>England &amp; Wales</td>
<td>2008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scotland</td>
<td>2007</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oceania</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Zealand</td>
<td>2007</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Australia</td>
<td>2008</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## What Will You Learn?

- What “cost-effectiveness” means for drug products and how payers perceive their value
- How patient outcomes fit into pharmacoeconomics
- The role that pharmacoeconomics plays in the drug development cycle
I'm worried and concerned.

GI symptoms bother me!

I cannot bend over or exercise.

Heartburn disturbs my sleep.

My whole life is affected.

I cannot eat and drink whatever I like.

Patient Outcomes Assessment Sources and Examples

Clinic - Reported

For Example:
Global impressions
Observation & tests of function

Physiological

For Example:
FEV1, HbA1c, Tumor size

Caregiver - Reported

For Example:
Dependency, Functional status

Patient - Reported

For Example:
Global impression
Functional status
Well-being
Symptoms
Satisfaction with TX
Treatment adherence
Health-Related Quality of Life (HRQL)

A person’s subjective perception of the impact of health status, including disease and treatment, on physical, psychological, and social functioning and well-being

(Leidy, Revicki, Geneste, 1999)

Patient-Reported Outcome Study Methods

**With what?**
- Validated questionnaires
- “Generic” or disease-specific instruments

**In Clinical Trials**
- As a primary or secondary endpoint
- Tested for clinically meaningful differences due to treatment
- May be included in drug labeling

**Other sources**
- Electronic medical record
- Disease-specific patient registry
- On-line surveys
What Will You Learn?

- What “cost-effectiveness” means for drug products and how payers perceive their value
- How patient outcomes fit into pharmacoeconomics
- The role that pharmacoeconomics plays in the drug development cycle

Terminology Note: “Pharmacoeconomics” is an aspect of the broader field of “Outcomes Research”; sometimes the terms are used together or interchangeably.

Outcomes Research and the Product Cycle

- Initial awareness, preliminary planning
- Discovery Research
- Exploratory Development
- Full Development
- Registration Period
- Launch
- Growth & Maintenance
- Early evaluation & strategic planning
Outcomes Research and the Product Cycle

Initial awareness, preliminary planning

OR Study Execution

Discovery Research
Exploratory Development
Full Development
Registration Period
Launch
Growth & Maintenance

Early evaluation & strategic planning

Outcomes Research and the Product Cycle

Initial awareness, preliminary planning

OR Study Execution

Discovery Research
Exploratory Development
Full Development
Registration Period
Launch
Growth & Maintenance

Early evaluation & strategic planning

Value dossiers sent & RWD studies initiated
Outcomes Research and the Product Cycle

Discovery Research
- Initial awareness, preliminary planning
- Exploratory Development
- Full Development
- Registration Period
- Launch
- Growth & Maintenance
- Early evaluation & strategic planning
- Value dossiers sent & RWD studies initiated

HEOR Evidence-Generating Tools

**Pre-launch**
- Early economic models for price-efficacy
- PRO instrument development and RCT use
- Burden of illness studies with real world data
- RCT-based HE analyses
- Full economic models (Cost-effectiveness/Budget Impact)
- Indirect/mixed treatment comparisons
- Dossiers

**Post-launch**
- Phase 4 prospective studies with HE components and/or analyses
- Registry and EMR design and analysis
- Comparative effectiveness research with real-world data
- Studies done in partnership with payers
- Employer studies/models

*Can be used in preparation for P&R negotiations*

*Can be used to support pull-through, responses to new market issues, and P&R reviews*
Summary

- Pharmacoeconomics measures the “value for money” brought to society by drug treatments, drawing its methods from health economics more broadly.

- Patient benefits, including quality of life benefits, from treatment must be scientifically captured, both to properly assess value and to better communicate treatment effects to patients and physicians.

- Payers across the world are increasingly using pharmacoeconomic results in their reimbursement decisions.

- Pharmacoeconomic work is done during all parts of the drug development cycle and helps inform product development strategy.
What You Will Learn

I. IP Considerations in New Drug Development

II. Most Important IP Policies Affecting New Drug Development

III. How IP Protection and Enforcement Decisions Are Made
I. IP Considerations in New Drug Development

- Patents
- Trademarks
- Trade Dress
- Trade Secrets
- Copyrights
II. Most Important IP Policies Affecting New Drug Development

- IP Landscape
  - U.S.
  - Europe
  - Asia
  - R.O.W.
- Pharmacoeconomics
- Regulation
  - U.S.
  - Europe

Audience Survey Question

Are you familiar with patent enforcement under Hatch-Waxman?

- No
- Heard of it
- Somewhat familiar
- Very familiar
III. How IP Protection and Enforcement Decisions Are Made

A. Innovator

B. Generics

C. Biotechnology
A. Innovator Drug Companies

<table>
<thead>
<tr>
<th>Sophisticated IP Departments</th>
<th>Focus on Patent Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Patent</td>
<td>- Compounds</td>
</tr>
<tr>
<td>- Trademark</td>
<td>- Compositions</td>
</tr>
<tr>
<td>- Marketing &amp; Advertising</td>
<td>- Methods</td>
</tr>
<tr>
<td></td>
<td>- Structure</td>
</tr>
<tr>
<td></td>
<td>- Dosage Requirements</td>
</tr>
<tr>
<td></td>
<td>- Treatment Protocols</td>
</tr>
</tbody>
</table>

A. Innovator Drug Companies

- Portfolio Development
- Patent Timelines
  - Normal 20 year term
  - Term Extensions
  - Improvement patents
B. Generic Drug Companies

- Hatch-Waxman Timeline
- Sophisticated IP Management
  - Most in-house
  - Combinations with Outside Counsel

C. Biotechnology Companies

- Only 40 years old
- Many Startups
  - Outside Patent Counsel
  - Innovative, Creative, Risk Takers
  - Reliance on Big Pharma for Drug Development
Hatch-Waxman Act

- 1984 Drug Price Competition and Patent Term Restoration Act
- Amended Federal Food Drug and Cosmetic Act
- Governs generic drug product’s entry into the market place
- Designed to protect the interest of the innovator drug companies while increasing the availability of generic drugs

NDA

- An innovator company must file a New Drug Application with the FDA to obtain approval to market its product

- NDA includes:
  - Full reports of investigation showing the drug is safe and effective
  - List of components of the drug
  - Description of methods facilities and controls used for producing the drug
  - Samples of drug and manufacturing components
  - Labeling information
  - Patent Information
Orange Book

Patents listed in an approved NDA are published in the FDA’s Approved Drug Products With Therapeutic Equivalence Evaluations

Purple Book

Newly created list under new regulations for Biosimilars
ANDA

• A manufacturer seeking to market a generic version of an FDA approved drug can file an abbreviated new drug application (ANDA)

• “Safe Harbor” under Hatch-Waxman Act to conduct research to develop information for an ANDA submission

ANDA

Applicant relies on safety and effectiveness finding of FDA for the innovator drug if generic product is therapeutically equivalent to Orange Book listed drug

A. Pharmaceutically equivalent

B. Bioequivalent
ANDA Certifications

• Applicant must make one of the following certifications:
  1. There are no patents listed for the drug
  2. The patents listed for the drug are expired
  3. The patents listed for the drug will expire on a particular future date
  4. The patents listed for the drug are invalid or will not be infringed by the generic drug

Patent Infringement Litigation

For certification of invalidity or non-infringement

• ANDA applicant gives notice to NDA holder within 20 days

• Statutory act of infringement under Hatch-Waxman
Patent Infringement Litigation

- Litigation to be filed by NDA holder within 45 days of Notice Letter

- Results:

  a) 30 month stay of FDA’s approval of ANDA

  b) 180 day period of exclusivity

    – *i.e.*, FDA cannot approve any subsequently filed ANDA’s

    – period begins on date ANDA files begins to market the generic product

Settlements

1. Highly Controversial in recent years

2. Must be reported to Federal Trade Commission and Department of Justice

3. Pay for Delay – Antitrust Challenges
Thank you

“Pharmacoeconomics and IP Strategies in Drug Development”

Dr. Robert Koch
Partner and IP Specialist, Milbank

Dr. Joseph Fortunak
Professor of Chemistry, Howard University

Dr. Richard Wilike
VP of Outcomes & Evidence, Pfizer

Recordings will be available to ACS members after three weeks

www.acs.org/acsw webinars

Contact ACS Webinars® at acsw webinars@acs.org
Next in the Drug Discovery Series!

“Future of Drug Discovery: Challenges, Risks, and Rewards”

Thursday, October 30, 2014

Upcoming ACS Webinars®

www.acs.org/acswebinars

Thursday, October 2, 2014

“The Chemistry of Death”

Lucas Zarwell, Chief Toxicologist, DC Medical Examiner’s Office
Dr. Darren Griffin, Professor of Genetics, University of Kent

Thursday, October 9, 2014

“From Molecules to Medicine: How Structure Helps Cure Disease”

Dr. Greg Petsko, Weill Cornell Medical College
Dr. Martha Teeter, American Crystallographic Association

Contact ACS Webinars® at acswebinars@acs.org
“Pharmacoeconomics and IP Strategies in Drug Development”

Dr. Robert Koch
Partner and IP Specialist, Milbank

Dr. Joseph Fortunak
Professor of Chemistry, Howard University

Dr. Richard Wilke
VP of Outcomes & Evidence, Pfizer

Recordings will be available to ACS members after three weeks
www.acs.org/acswebinars

Contact ACS Webinars ® at acswebinars@acs.org

How has ACS Webinars® benefited you?

“In my opinion, The Role of Chemistry in Clinical Trials was the best webinar presented in the series. There was a balance between theory and practice. The key studies were very interesting. The speakers were relaxed and confident in their knowledge, I felt like I was participating in a meeting of masters.”

Fan of the Week
Dr. Alicja Kluczyk
Faculty of Chemistry
University of Wroclaw
Wroclaw, Poland

Be a featured fan on an upcoming webinar! Write to us @ acswebinars@acs.org
ACS Short Courses

Monday - Thursday, October 6-9, 2014
Boston, MA

Courses scheduled to be held include:

- Critical cGMP and ICH regulations for Pharmaceutical Laboratories
- Drug-like Properties: Optimizing Pharmacokinetics and Safety in Drug Discovery
- Analytical Method Transfer of Pharmaceutical Products

Register at http://proed.acs.org/Boston
Benefits of ACS Membership

Chemical & Engineering News (C&EN)
The preeminent weekly news source.

NEW! Free Access to ACS Presentations on Demand®
ACS Member only access to over 1,000 presentation recordings from recent ACS meetings and select events.

NEW! ACS Career Navigator
Your source for leadership development, professional education, career services, and much more.

www.acs.org/2joinACS

ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of the American Chemical Society.

Contact ACS Webinars® at acswебinars@acs.org
Upcoming ACS Webinars®
www.acs.org/acswebinars

Thursday, October 2, 2014
“The Chemistry of Death”
Lucas Zarwell, Chief Toxicologist, DC Medical Examiner’s Office
Dr. Darren Griffin, Professor of Genetics, University of Kent

Thursday, October 9, 2014
“From Molecules to Medicine: How Structure Helps Cure Disease”
Dr. Greg Petsko, Weill Cornell Medical College
Dr. Martha Teeter, American Crystallographic Association

Contact ACS Webinars® at acswebinars@acs.org